VRDN Key Statistics, Chart & Performance
The current stock price of VRDN is 31.75 USD. In the past month the price decreased by -2.61%. In the past year, price increased by 74.45%.
VRDN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About VRDN
Company Profile
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
Company Info
VIRIDIAN THERAPEUTICS INC
221 Crescent Street, Suite 103A
Waltham MASSACHUSETTS 80301 US
CEO: Jonathan Violin
Employees: 143
Phone: 16172724600
VIRIDIAN THERAPEUTICS INC / VRDN FAQ
What does VRDN do?
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 143 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.
What is the stock price of VIRIDIAN THERAPEUTICS INC today?
The current stock price of VRDN is 31.75 USD. The price increased by 4.68% in the last trading session.
Does VIRIDIAN THERAPEUTICS INC pay dividends?
VRDN does not pay a dividend.
What is the ChartMill rating of VIRIDIAN THERAPEUTICS INC stock?
VRDN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about VIRIDIAN THERAPEUTICS INC (VRDN) stock?
24 analysts have analysed VRDN and the average price target is 39.59 USD. This implies a price increase of 24.69% is expected in the next year compared to the current price of 31.75.
What is the Price/Earnings (PE) ratio of VIRIDIAN THERAPEUTICS INC (VRDN)?
VIRIDIAN THERAPEUTICS INC (VRDN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.21).
Is VIRIDIAN THERAPEUTICS INC (VRDN) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on VRDN.
VRDN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to VRDN. When comparing the yearly performance of all stocks, VRDN is one of the better performing stocks in the market, outperforming 94.21% of all stocks.
VRDN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to VRDN. The financial health of VRDN is average, but there are quite some concerns on its profitability.
VRDN Financial Highlights
Over the last trailing twelve months VRDN reported a non-GAAP Earnings per Share(EPS) of -3.21. The EPS increased by 25.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.32% | ||
| ROE | -60.04% | ||
| Debt/Equity | 0.04 |
VRDN Forecast & Estimates
24 analysts have analysed VRDN and the average price target is 39.59 USD. This implies a price increase of 24.69% is expected in the next year compared to the current price of 31.75.
For the next year, analysts expect an EPS growth of -6.82% and a revenue growth 24620.2% for VRDN